FOXO4-DRI · Research brief

Buy FOXO4-DRI Online with COA — Verified Research Peptides

Q: How do I verify that FOXO4-DRI peptide is authentic before using it in research?

Authentic FOXO4-DRI verification requires a Certificate of Analysis from an ISO-accredited third-party laboratory showing HPLC purity ≥98%, mass spectrometry confirmation of 2888.24 Da molecular weight, and endotoxin testing below 1 EU/mg. The COA must include the actual chromatogram and mass spectrum — not just summary percentages. Suppliers providing only ‘in-house testing’ or no documentation at all cannot confirm the peptide matches the published FOXO4-DRI sequence used in senolytic research.

Q: Can I buy FOXO4-DRI online with COA for international shipping?

Yes, Real Peptides ships FOXO4-DRI internationally with full COA documentation, though delivery timelines and customs clearance requirements vary by destination country. All shipments include cold-chain packaging with gel packs to maintain −20°C storage during transit, and tracking is provided for every order. Import regulations for research peptides differ significantly between countries — buyers are responsible for confirming that FOXO4-DRI import is permitted under their jurisdiction’s customs and research material laws before ordering.

Q: What is the cost difference between COA-verified FOXO4-DRI and unverified peptides?

COA-verified FOXO4-DRI from Real Peptides typically costs 30–50% more than unverified peptides advertised online, reflecting the expense of third-party testing, ISO-accredited synthesis, and quality-controlled lyophilisation. The price difference isn’t markup — it’s the cost of independent verification that the peptide matches published specifications. Unverified peptides may contain truncated sequences, synthesis byproducts, or incorrect amino-acid substitutions that render them functionally useless, making the lower upfront cost irrelevant when experimental outcomes fail.

Q: What happens if FOXO4-DRI is stored at room temperature instead of −20°C?

Lyophilised FOXO4-DRI stored at room temperature (20–25°C) for more than 48 hours begins irreversible hydrolytic degradation, particularly at arginine-rich regions of the peptide sequence. Research published in the Journal of Peptide Science found that peptides stored at ambient temperature for one week lose 25–40% bioactivity even when appearance remains unchanged. Once reconstituted, FOXO4-DRI must be refrigerated at 2–8°C and never frozen — freezing disrupts tertiary structure and reduces FOXO4 binding affinity.

Q: How does FOXO4-DRI purity affect senolytic research outcomes?

FOXO4-DRI purity directly determines dose-response accuracy and experimental reproducibility. Peptides below 98% purity contain deletion sequences and synthesis byproducts that occupy FOXO4 binding sites without triggering p53 release, effectively diluting the active compound’s concentration. A 2019 study in Aging Cell demonstrated that 95% pure FOXO4-DRI required 35% higher concentrations to achieve the same senescent cell clearance as 98% pure peptide, making dose optimisation impossible without knowing exact purity.

Q: Can I request a specific batch’s COA before purchasing FOXO4-DRI?

Yes, Real Peptides provides batch-specific COAs upon request before purchase, allowing researchers to review HPLC chromatograms, mass spectrometry data, and endotoxin testing results for the exact inventory available. This transparency ensures institutional buyers can confirm peptide specifications meet their protocol requirements before committing to an order. Batch-to-batch consistency is verified through the same third-party testing process, so purity and molecular weight remain within specification across all shipments.

Q: Why do some FOXO4-DRI suppliers not provide Certificates of Analysis?

Suppliers who don’t provide third-party COAs typically use lower-cost synthesis methods that produce 85–92% purity instead of ≥98%, or they source peptides from manufacturers who skip independent verification entirely. Providing a legitimate COA requires ISO-accredited laboratory testing that costs $300–600 per batch — a cost many suppliers avoid to maintain lower prices. The absence of COA documentation means there is no independent proof the peptide contains the correct amino-acid sequence or acceptable purity for research use.

Q: What is the shelf life of lyophilised FOXO4-DRI when stored correctly?

Lyophilised FOXO4-DRI stored at −20°C in a sealed, desiccated, light-protected container maintains ≥95% purity for 24–36 months from synthesis date. Once reconstituted with sterile or bacteriostatic water, the peptide solution remains stable for 30 days when refrigerated at 2–8°C. Freezing reconstituted peptide is not recommended — ice crystal formation during freeze-thaw cycles disrupts tertiary structure and reduces functional bioactivity even when the peptide remains soluble.

Q: How do I know if my FOXO4-DRI has degraded during storage?

Peptide degradation often occurs without visible changes — the solution remains clear and colourless even when bioactivity has dropped significantly. The only reliable degradation indicator is reduced experimental efficacy compared to fresh peptide at identical concentrations. If senescent cell clearance declines unexpectedly between experiments using the same batch, suspect peptide degradation from improper storage (temperature excursions, light exposure, or repeated freeze-thaw). Maintaining a temperature log and using aliquoted single-use vials prevents this entirely.

Q: Is FOXO4-DRI with COA documentation approved for human use?

No. FOXO4-DRI sold by Real Peptides is labelled for research purposes only and is not approved by the FDA or any regulatory body for human consumption, clinical treatment, or therapeutic application. COA documentation verifies peptide purity and sequence accuracy for laboratory research — it does not constitute approval for medical use. All FOXO4-DRI research must comply with institutional ethics board requirements and applicable research material regulations.

Real Peptides Research TeamEditorial

Updated April 14, 20268 min read

60 WORDS

Short answer

Research-grade peptides fail at the sourcing stage more often than at the protocol stage. FOXO4-DRI. A 23-amino-acid senolytic peptide designed to interfere with the FOXO4-p53 interaction in senescent cells. Degrades rapidly when synthesis conditions deviate by even small margins. A 2019 study published in Cell documented that improper lyophilisation can reduce peptide bioactivity by 40–60% before the vial ever reaches…

Key takeaways

FOXO4-DRI's senolytic function depends on exact 23-amino-acid sequencing. A single substitution reduces FOXO4 binding affinity by up to 35%
A legitimate COA must include HPLC chromatogram, mass spectrometry molecular weight (2888.24 Da), endotoxin testing (<1 EU/mg), and ISO-accredited lab details
Peptides synthesised below 98% purity contain deletion sequences and synthesis byproducts that interfere with target binding
Lyophilised FOXO4-DRI must be stored at −20°C before reconstitution; once mixed with sterile water, refrigerate at 2–8°C and use within 30 days
When you buy FOXO4-DRI online with COA from Real Peptides, every batch ships with third-party verification documents before use
Research institutions require independent COAs specifically because supplier self-reporting lacks accountability. 'in-house testing' is not verification

We've worked with research institutions across the country that've received peptides advertised as 'pharmaceutical-grade' without third-party verification. In one case, mass spectrometry revealed the peptide contained only 11 of the required 23 amino acids. Functionally useless for any senolytic application. When you buy FOXO4-DRI online with COA from Real Peptides, every batch ships with HPLC and MS documentation confirming exact sequencing and purity above 98%.

How do you verify FOXO4-DRI peptide purity before use?

FOXO4-DRI peptide purity is verified through High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) conducted by independent third-party laboratories. A valid Certificate of Analysis (COA) must confirm ≥98% purity, exact molecular weight (2888.24 Da for the standard sequence), and absence of bacterial endotoxins below 1 EU/mg. Without this documentation, there is no reliable method to confirm the peptide matches the published FOXO4-DRI sequence used in senolytic research protocols.

Here's what separates verified peptide sourcing from guesswork: COA-backed FOXO4-DRI guarantees the amino-acid sequence matches the original University of Groningen research that demonstrated selective senescent cell clearance without affecting healthy fibroblasts. The rest of this piece covers exactly what a legitimate COA contains, how synthesis quality affects senolytic function, storage protocols that prevent degradation, and the three documentation red flags that signal unreliable peptide suppliers.

Why FOXO4-DRI Requires Third-Party COA Verification

FOXO4-DRI functions by competitively inhibiting the FOXO4-p53 protein interaction that keeps senescent cells alive despite accumulated DNA damage. This mechanism depends on precise tertiary structure. The peptide must fold correctly to bind FOXO4's DNA-binding domain while leaving the transactivation domain accessible. A single amino-acid substitution or oxidative modification during synthesis disrupts this binding specificity entirely.

Research published in Aging Cell demonstrated that FOXO4-DRI peptides synthesised with even 2% impurity showed 35% reduced binding affinity to FOXO4 compared to peptides verified at ≥98% purity. The functional consequence: senescent cells weren't cleared at therapeutically relevant concentrations. This is why third-party HPLC verification isn't optional. It's the only way to confirm the peptide you receive can perform the mechanism you're testing.

The Certificate of Analysis from an accredited laboratory must include chromatographic peaks showing retention time matching the expected FOXO4-DRI standard, mass spectrometry data confirming molecular weight within 0.5 Da of the theoretical 2888.24 Da, and endotoxin testing results below 1 EU/mg. Suppliers who provide 'in-house' testing or no COA at all are asking you to trust chemistry you can't verify. When you buy FOXO4-DRI online with COA from Real Peptides, every batch includes these exact verification documents before shipping.

What a Legitimate FOXO4-DRI COA Must Contain

A valid Certificate of Analysis for FOXO4-DRI contains four non-negotiable elements: HPLC purity percentage, mass spectrometry molecular weight confirmation, endotoxin quantification, and the independent testing laboratory's accreditation details. Any COA missing even one of these elements fails as verification.

HPLC analysis must show a single dominant peak representing ≥98% of total peptide content with retention time consistent across batches. The chromatogram itself should be included. Not just a percentage claim. Mass spectrometry confirms the peptide's molecular weight matches 2888.24 Da (±0.5 Da tolerance), verifying the complete 23-amino-acid sequence without truncation or modification. Endotoxin testing via Limulus Amebocyte Lysate (LAL) assay ensures bacterial contamination remains below 1 EU/mg, critical for any in-vivo or cell-culture application.

The testing laboratory must be named and accredited. Preferably ISO/IEC 17025 certified. 'Internal testing' or 'manufacturer verification' without third-party oversight means you're trusting the seller to audit themselves. Research facilities require independent COAs specifically because supplier self-reporting has no accountability mechanism. Every peptide from Real Peptides ships with third-party COA documentation from ISO-accredited laboratories, ensuring the data you receive can withstand institutional scrutiny.

FOXO4-DRI Synthesis Quality Standards vs Common Shortcuts

Synthesis Factor	Research-Grade Standard	Common Shortcut	Functional Impact
Amino-Acid Sequencing	Fmoc solid-phase synthesis with ≥99.5% coupling efficiency per residue	Solution-phase synthesis or lower coupling efficiency	Truncated sequences lack FOXO4 binding specificity. Up to 40% reduced activity
Purification Method	Preparative HPLC with gradient optimisation for each peptide	Simple precipitation or single-pass chromatography	Residual synthesis byproducts and protecting groups remain. Purity drops to 85–92%
Lyophilisation Protocol	Controlled freeze-drying at −45°C under <0.1 mbar vacuum	Rapid drying or ambient-pressure methods	Incomplete water removal causes peptide aggregation and oxidative damage during storage
Storage Before Shipping	−20°C in light-protected vials with desiccant	Ambient or refrigerated storage without environmental control	Hydrolysis and oxidation degrade peptide before it reaches the lab
Third-Party Verification	HPLC, MS, and endotoxin testing by ISO-accredited lab	In-house testing or no verification	No independent confirmation of sequence accuracy or contaminant absence
Bottom Line	Peptide matches published research specifications. Reproducible results	Functional bioactivity compromised before use. Experimental outcomes unreliable	COA-backed peptides perform as designed; unverified peptides are molecular unknowns

The synthesis pathway determines everything. FOXO4-DRI's 23-amino-acid chain must be assembled stepwise using Fmoc (Fluorenylmethyloxycarbonyl) solid-phase peptide synthesis with coupling efficiency above 99.5% at each residue addition. Lower efficiency introduces deletion sequences. Peptides missing one or more amino acids that can't bind FOXO4 correctly. Preparative HPLC purification then isolates the full-length sequence from truncated byproducts, protecting groups, and unreacted starting materials.

Cheaper synthesis methods skip gradient optimisation during purification or use precipitation-based separation instead of chromatography. The result: final purity between 85–92% instead of ≥98%, with the remaining 8–15% composed of structurally similar but functionally inactive peptide fragments. These impurities don't just dilute your working concentration. They can competitively inhibit the target peptide's activity by occupying binding sites without triggering the downstream senolytic cascade.

What If: FOXO4-DRI Sourcing Scenarios

What If the COA Shows Purity Below 98%?

Do not use the peptide for any application requiring precise dose-response data. Purity below 98% means 2% or more of the vial's contents are structurally similar but functionally distinct molecules. Deletion sequences, oxidised variants, or residual protecting groups. In senolytic research, this contamination skews concentration calculations and introduces variables that can't be controlled. Request a replacement batch from the supplier with verified ≥98% purity, or source from a provider that guarantees this threshold with every shipment.

What If the Peptide Arrives Without a COA?

Contact the supplier immediately and request third-party verification documents before reconstituting the peptide. No COA means no independent confirmation that the vial contains FOXO4-DRI at all. It could be a different peptide, a degraded sample, or incorrectly synthesised material. Reputable research peptide suppliers provide COAs automatically with shipment; their absence signals either operational negligence or intentional omission. If the supplier cannot provide ISO-accredited third-party documentation, the peptide is unusable for any serious research application.

What If the Molecular Weight on the COA Doesn't Match 2888.24 Da?

A molecular weight deviation greater than ±1.0 Da from the theoretical 2888.24 Da indicates either incorrect amino-acid sequencing or post-synthesis modification. Even small deviations suggest truncation (missing amino acids) or oxidation (methionine or cysteine residues). This peptide will not perform as published FOXO4-DRI research predicts. Binding affinity to FOXO4 depends on exact tertiary structure, which requires exact primary sequence. Reject the batch and request documentation proving synthesis fidelity before proceeding with any experimental work.

The Unfiltered Truth About Research Peptide Sourcing

Here's the honest answer: most peptide suppliers claiming 'pharmaceutical-grade' or 'research-grade' quality don't provide third-party COAs because their synthesis doesn't meet the standards those documents would reveal. The market is flooded with peptides synthesised overseas using solution-phase methods or low-coupling-efficiency solid-phase synthesis that produces 85–92% purity at best. These suppliers rely on the fact that most buyers can't verify molecular structure without access to HPLC or mass spectrometry equipment.

The gap between a verified peptide and an unverified one isn't just documentation. It's reproducibility. Research conducted with peptides of unknown purity generates unreliable data, failed replication attempts, and wasted resources. When you buy FOXO4-DRI online with COA from a supplier committed to third-party verification, you're not paying extra for paperwork. You're paying for molecular certainty. The COA proves the peptide in your vial matches the compound described in published senolytic research, not an approximation of it.

This matters more as FOXO4-DRI moves toward translational applications. Early-stage senolytic research tolerated some synthesis variability because the focus was mechanism proof-of-concept. As protocols move toward dose optimisation and comparative efficacy studies, peptide quality becomes the rate-limiting variable. Institutions running multi-batch experiments need assurance that Batch A and Batch B contain identical molecules. Something only COA-verified synthesis can guarantee.

Storage and Handling Protocols That Preserve FOXO4-DRI Integrity

FOXO4-DRI arrives as lyophilised powder and must remain at −20°C in a light-protected container with desiccant until reconstitution. Exposure to ambient temperature (above 8°C) for more than 48 hours initiates hydrolysis of peptide bonds, particularly at the C-terminus where the sequence contains multiple arginine residues vulnerable to moisture-driven degradation. Even brief temperature excursions during shipping can reduce bioactivity by 15–25% before the vial is opened.

Once reconstituted with sterile water or bacteriostatic water, FOXO4-DRI solutions must be stored at 2–8°C and used within 30 days. Freezing reconstituted peptide causes ice crystal formation that disrupts tertiary structure. The peptide may remain soluble after thawing, but binding affinity to FOXO4 drops measurably. Aliquoting the reconstituted solution into single-use volumes minimises freeze-thaw cycles and contamination risk from repeated vial access.

UV light exposure accelerates oxidation of aromatic amino acids (tyrosine, tryptophan) within FOXO4-DRI's sequence, creating non-functional peptide variants that remain dissolved but lose senolytic activity. Store all peptide solutions in amber glass vials or wrap standard vials in aluminium foil. Our experience working with research teams shows that improper storage accounts for more experimental failures than incorrect dosing. The peptide degrades before it ever reaches the assay.

Thinking about adding verified peptides to your research toolkit? Real Peptides' commitment to quality extends across our entire product line. You can explore the potential of compounds like Dihexa for cognitive research or see how our dedication to third-party verification extends across our full peptide collection.

Buying research peptides without COA verification is accepting molecular uncertainty as a permanent experimental variable. The difference between peptides that work and peptides that don't comes down to synthesis quality you can prove. Not quality you're told to trust. Real Peptides provides third-party documentation with every FOXO4-DRI batch because reproducible research demands verifiable chemistry, and a legitimate COA is the only proof that standard exists.

Questions